RXRX
RXRX
US75629V1044
Recursion Pharmaceuticals, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 74.256.000 58.488.000
27.0%
Cost of Revenue 70.953.000 45.238.000
56.8%
Gross Profit 3.303.000 13.250.000
75.1%
651.435.000 492.254.000
32.3%
Operating Income -648.132.000 -479.004.000
35.3%
Pretax Income -644.895.000 -464.788.000
38.8%
Net Income Common Stockholders -644.759.000 -463.661.000
39.1%
-- --
--
-- --
--
ende